Skip to main content

A Randomized multicenter double blind Phase III study of Nivolumab or placebo in subjects with resected esophageal junction cancer.

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Bristol-Myers Squibb Company

Start Date

July 1, 2016

End Date

June 30, 2023
 

Administered By

Duke Cancer Institute

Awarded By

Bristol-Myers Squibb Company

Start Date

July 1, 2016

End Date

June 30, 2023